---
title: "CEVIRA, a non-invasive therapy for cervical precancerous lesions, approved in China by Asieris Pharmaceuticals."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277602183.md"
description: "Photocure ASA, a leading player in bladder cancer treatment (OSE: PHO), has reported through its partner Asieris Pharmaceuticals (SSE: 688176) that APL-1702, known as CEVIRA®, has obtained the Drug Registration Certificate. This significant milestone was achieved as of March 3, 2026, marking a major advancement for the companies involved."
datetime: "2026-03-03T09:54:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277602183.md)
  - [en](https://longbridge.com/en/news/277602183.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277602183.md)
generator: "portal-rs"
---

# CEVIRA, a non-invasive therapy for cervical precancerous lesions, approved in China by Asieris Pharmaceuticals.

Photocure ASA, a leading player in bladder cancer treatment (OSE: PHO), has reported through its partner Asieris Pharmaceuticals (SSE: 688176) that APL-1702, known as CEVIRA®, has obtained the Drug Registration Certificate. This significant milestone was achieved as of March 3, 2026, marking a major advancement for the companies involved.

### Related Stocks

- [688176.CN](https://longbridge.com/en/quote/688176.CN.md)

## Related News & Research

- [RemeGen Deploys Idle Funds Into Discloseable Wealth Management Products](https://longbridge.com/en/news/297779978.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [China Resources Pharma unit KPC wins registration to issue RMB 1 billion in medium-term notes](https://longbridge.com/en/news/297630970.md)
- [Gen Ilac Shares Shift to Call Auction After Circuit Breaker Halt](https://longbridge.com/en/news/297934526.md)
- [Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule](https://longbridge.com/en/news/297892535.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**